Clinical Trials Directory

Trials / Unknown

UnknownNCT04423198

HEAD Injury Serum Markers and Multi-modalities for Assessing Response to Trauma

HEAD Injury Serum Markers and Multi-modalities for Assessing Response to Trauma II

Status
Unknown
Phase
Study type
Observational
Enrollment
2,000 (estimated)
Sponsor
BRAINBox Solutions Inc · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The goal of HeadSMART II (HEAD injury Serum markers and Multi-modalities for Assessing Response to Trauma II) is to develop an In-Vitro Diagnostic, the BRAINBox TBI test, to aid in the diagnosis and prognosis of patients with mild traumatic brain injury, by incorporating blood biomarkers, clinical assessments, and tools to measure associated neurocognitive impairments.

Detailed description

This study proposes to collect data using a multi-modality approach including blood biomarkers, clinical assessments, neurocognitive performance, and neuropsychological characteristics, to identify subjects with a mild Traumatic Brain Injury (TBI) and their likelihood of chronic symptoms. This is an observational study with an expectation of enrolling up to 2000 subjects. These subjects will include the intended use population, subjects presenting to the Emergency Department or Urgent Care with a blunt head trauma. Data will be collected across four time points, T=0, 14 days, 30 days and 90 days, to allow for building and validating the algorithms for both diagnosis and prognosis claims. Control populations, healthy and trauma only (no head trauma) will be included for assay development. Data will be collected for these groups at T=0 and 14 days (trauma control only).

Conditions

Interventions

TypeNameDescription
BEHAVIORALCognitive AssessmentSelf administered cognitive battery
BEHAVIORALPatient Reported Neurological Outcome AssessmentsStandard neurocognitive and neuropsychological tests
PROCEDUREBlood DrawSpecimen collection of whole blood, serum, RNA

Timeline

Start date
2020-12-31
Primary completion
2021-12-01
Completion
2021-12-01
First posted
2020-06-09
Last updated
2021-08-04

Locations

11 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT04423198. Inclusion in this directory is not an endorsement.